Mosseri Marlio Charles 4/A
4/A · Nuvectis Pharma, Inc. · Filed May 12, 2025
Insider Transaction Report
Form 4/AAmended
Mosseri Marlio Charles
10% Owner
Transactions
- Purchase
Common Stock
2025-05-09$8.90/sh+9,817$87,412→ 2,931,199 total(indirect: By Emerald Hill Ventures SARL SPF.) - Purchase
Common Stock
2025-05-08$8.71/sh+100$871→ 2,909,132 total(indirect: By Emerald Hill Ventures SARL SPF.) - Purchase
Common Stock
2025-05-09$8.95/sh+9,850$88,128→ 2,921,382 total(indirect: By Emerald Hill Ventures SARL SPF.) - Purchase
Common Stock
2025-05-08$8.99/sh+100$899→ 2,909,032 total(indirect: By Emerald Hill Ventures SARL SPF.) - Purchase
Common Stock
2025-05-09$8.98/sh+5,395$48,426→ 2,936,594 total(indirect: By Emerald Hill Ventures SARL SPF.) - Purchase
Common Stock
2025-05-08$8.97/sh+2,400$21,528→ 2,911,532 total(indirect: By Emerald Hill Ventures SARL SPF.)
Footnotes (3)
- [F1]Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL.
- [F2]The original Form 4, filed on May 9, 2025, is being amended by this Form 4 amendment to correct the price of securities acquired by the reporting in the reported transactions.
- [F3]The original Form 4, filed on May 9, 2025, is being amended by this Form 4 amendment to include transactions that occurred on May 9, 2025.